Shares of CryoLife Inc. (NYSE:CRY) have been given a consensus rating of “Buy” by the six research firms that are covering the firm. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $15.25.
CRY has been the subject of several recent analyst reports. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “strong-buy” rating and set a $18.00 price target for the company in a report on Friday, August 12th. Lake Street Capital initiated coverage on CryoLife in a report on Wednesday, June 15th. They issued a “buy” rating and a $15.00 price target for the company. Canaccord Genuity restated a “buy” rating on shares of CryoLife in a report on Tuesday, July 26th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $16.00 price target on shares of CryoLife in a report on Wednesday, July 27th.
CryoLife (NYSE:CRY) traded down 0.06% during mid-day trading on Tuesday, hitting $17.81. 159,548 shares of the company were exchanged. CryoLife has a 12 month low of $8.94 and a 12 month high of $18.64. The firm has a 50 day moving average price of $16.46 and a 200 day moving average price of $13.06. The stock has a market cap of $607.50 million, a price-to-earnings ratio of 57.08 and a beta of 1.14.
CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, July 25th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.11. The firm earned $47.10 million during the quarter, compared to analysts’ expectations of $35.50 million. CryoLife had a return on equity of 8.15% and a net margin of 5.80%. The firm’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS. Analysts anticipate that CryoLife will post $0.34 EPS for the current fiscal year.
In other news, Director C Elkins Ronald sold 2,000 shares of CryoLife stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $14.00, for a total value of $28,000.00. Following the transaction, the director now directly owns 103,586 shares of the company’s stock, valued at approximately $1,450,204. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.08% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Prudential Financial Inc. raised its position in CryoLife by 11.8% in the first quarter. Prudential Financial Inc. now owns 65,404 shares of the company’s stock valued at $703,000 after buying an additional 6,881 shares in the last quarter. BlackRock Fund Advisors raised its position in CryoLife by 1.1% in the first quarter. BlackRock Fund Advisors now owns 1,642,615 shares of the company’s stock valued at $17,658,000 after buying an additional 18,349 shares in the last quarter. Royce & Associates LP raised its position in CryoLife by 10.6% in the first quarter. Royce & Associates LP now owns 731,200 shares of the company’s stock valued at $7,860,000 after buying an additional 70,000 shares in the last quarter. Spark Investment Management LLC raised its position in CryoLife by 217.6% in the first quarter. Spark Investment Management LLC now owns 39,700 shares of the company’s stock valued at $426,000 after buying an additional 27,200 shares in the last quarter. Finally, Adirondack Research & Management Inc. raised its position in CryoLife by 1.5% in the first quarter. Adirondack Research & Management Inc. now owns 277,123 shares of the company’s stock valued at $2,979,000 after buying an additional 4,200 shares in the last quarter. 58.13% of the stock is currently owned by institutional investors and hedge funds.
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.